Validation of Hemorrhoidal Bleeding Score

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The principal manifestation of hemorrhoidal disease is bleeding; however the severity evaluation is today based on prolapsus (Goligher classification) and bleeding factor is not included. Even if there was some rare score including bleeding in literature , none of them were validated. The aim of the study is first validation of bleeding score .

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT05089500` - The Two Treatment Methods Compared the Sclerosing Agent Injection and the Rubber Wrapping	N/A

NCT number	NCT03060616
Study type	Observational
Source	Groupe Hospitalier Paris Saint Joseph
Contact
Status	Completed
Phase
Start date	September 1, 2016
Completion date	March 15, 2018

Validation of Hemorrhoidal Bleeding Score

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms